Whooping Cough Remains a Formidable Opponent Against Vaccination
In 1976, public health officials celebrated when whooping cough cases dropped to 1,010—the fewest ever reported. Before widespread vaccination against whooping cough, the disease infected up to 270,000 people a year, killing as many as 10,000, mostly infants. Just five years earlier, widespread vaccination against smallpox had worked so well that health officials retired the vaccine, raising hopes that whooping cough might follow a similar path. But whooping cough, or pertussis—named after the pathogenic bacterium Bordetella pertussis—has proven a far more formidable opponent.
In recent years, despite relatively high vaccination rates, the pathogen has come roaring back to infect people in numbers not seen since the pre-vaccine days. Several states suffered outbreaks last year, with more than 41,000 cases reported across the country. California’s epidemic hit in 2010, when more than 9,000 people fell ill—the highest number in more than 60 years—and 10 infants died. Pertussis has also rebounded in Europe. England and Wales saw a record number of cases in 2012, with more than 9,700 cases and 14 infant deaths.
Pertussis attacks the respiratory track to cause spasmodic coughing, vomiting and severe breathing problems as thick mucus clogs the lungs. Most deaths occur in babies because the buildup of mucus quickly overwhelms their still-developing blood vessels, depriving their lungs of oxygen. “It’s like they’re being strangled to death by this particular bacteria,” pediatrician Paul Offit says of watching a stricken child.
Although vaccination protects infants, babies younger than two months old—too young to receive the first of five recommended vaccinations—face the greatest risk of death. Nine of the 10 children who died during the California epidemic were less than two months old.
Several factors may account for recent pertussis outbreaks, including waning effectiveness of the vaccine, the evolution of more aggressive pathogens, a mismatch between the vaccine and the bacterium and increased awareness among health professionals. Following the California epidemic, researchers at Kaiser Permanente’s Vaccine Study Center tested the waning immunity hypothesis: the possibility that protection from the vaccine fades with time.
Before vaccines targeting B. pertussis were introduced in the 1940s, pertussis was a major cause of infant death worldwide, killing more children than polio, measles and tuberculosis combined. The original pertussis vaccine was made from killing the bacteria with chemicals, and combining the whole bacterium with weakened diphtheria and tetanus toxins in a vaccine called DTwP— “w” for “whole cell.” After concerns about the vaccine’s adverse effects—both real (episodes of high fever, fever with seizure, irritability, and a scary though short-lived condition called hypotonic hyporesponsive syndrome, in which children appear limp, unresponsive and pale) and unsupported by science (long term brain damage)—led to rising rates of vaccine refusal in the 1980s, vaccine developers formulated an acellular vaccine, DTaP, using isolated components of the pathogen.
By the late 1990s, the acellular version was used for all five recommended childhood doses. Although both vaccines offer protection against pertussis for a number of years, several studies suggest that immunity fades faster following DTaP vaccination. That’s why in 2005 the U.S. Advisory Committee on Immunization Practices started recommending booster shots for children 11 years and older and California now requires a pertussis booster for students entering seventh grade.
To determine the relative effectiveness of the two vaccines, the Kaiser researchers studied the health records of teenagers born between 1994 and 1999 to see if the vaccines they received as babies and toddlers affected their risk of getting pertussis during the 2010 epidemic. Because the new whole cell vaccine was phased in gradually, some children received just the old vaccine, some received both, and some got just the new vaccine. During the epidemic, 138 of the children in the study contracted pertussis.
The researchers found that children vaccinated with the acellular vaccine were nearly six times more likely to get the disease than children vaccinated with the discontinued whole cell vaccine. Protection appeared to be dose-related, the team noted, as children who received mixed vaccines faced an intermediate level of risk.The “Tdap” booster shot failed to bridge the gap in protection between those who received only whole cell vaccines and those who got just the acellular version.
Anytime a new vaccine is developed, scientists work to balance the vaccine’s effectiveness with the risk of side effects. “This is a very complex issue,” says pediatrician Nicola Klein, who led the Kaiser study. Health officials may need to add additional boosters of the acellular vaccine to compensate for waning immunity, for example. “But I don’t think there’s a willingness to go back to the whole cell vaccines, so the long-term strategy would be to develop new vaccines with reliable and lasting immunity.”
But that task will not be easy. It’s not exactly clear what components from the bacteria need to be included in the vaccine to produce a long-term effect on immunity, Klein says. “We thought the acellular vaccine would provide that. Clearly it’s not.”
Some researchers think pertussis strains are adapting to vaccination, either by producing more aggressive toxins or acquiring mutations that create a mismatch between the vaccine and the pathogen. Frits Mooi, a pertussis expert with the Netherlands Centre for Infectious Disease Control who was not involved in the Kaiser study, says that several studies now show that whole cell vaccines afford much longer protection than acelluar vaccines. But strain adaptation also increases the speed at which immunity wanes, he says.
“I think waning immunity is the compound effect of intrinsic qualities of the vaccine and pathogen adaptation,” Mooi says. What’s needed, he argues, is an integrated approach that accounts for interactions beween the vaccines and evolving pathogens. As far back as 1998, Mooi suggested that incorporating pertussis variants identified in circulating bacterial populations into a new acellular vaccine could make it more effective. Using genetic rather than chemical methods to detoxify pertussis toxins in vaccines could also prove more effective because genetically neutralized toxins can trigger a stronger immune response in our bodies.
Until a new vaccine is developed, Klein urges parents to vaccinate their children. Pertussis outbreaks cycle in three to five years and it’s been three years since California’s historic epidemic. “The take-home message for parents is that they really need to continue to get their kids vaccinated and to get them vaccinated on the recommended schedules,” she says. That includes ensuring that adolescents get their Tdap booster shot. “We know the acellular vaccine works. It just doesn’t last as long as we’d hoped.”Related